Business
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually. Details of the poster presentation Title: A biology-based, mathematical model to predict the response of recurrent glioblastoma to treatment with 186Re-labeled nanoliposomes Session Title: Mathematical Models Session Date and Time: Tuesday, April 12, 2022, 9:00 a.m. – 12:30 p.m. CT Location: New Orleans Convention Center, Exhibit Halls D – H, Poster Section 29 Poster Board Number: 13 Permanent Abstract Number: 2742 Link to Abstract: https://www.abstractsonline.com/pp8/#!/10517/presentation/18391 A copy of the poster presentation will be made available under the Presentations tab of the For Investors section of the Company’s website following the meeting at www.plustherapeutics.com. About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs,...